Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Ronan J Kelly

Showing results (11-20 of 109) with videos related to

Pageof 11
Sort By:
Targeted Oncology|October 31, 2009
Axitinib--a selective inhibitor of the vascular endothelial growth factor (VEGF) receptorRonan J Kelly, Olivier Rixe
Gastroenterology Research and Practice|March 19, 2015
From molecular classification to targeted therapeutics: the changing face of systemic therapy in metastatic gastroesophageal cancerAdrian Murphy, Ronan J Kelly
Hematology/Oncology Clinics of North America|May 15, 2017
The Evolving Role of Checkpoint Inhibitors in the Management of Gastroesophageal CancerAdrian G Murphy, Ronan J Kelly
Journal of Thoracic Disease|May 1, 2018
Single agent anti PD-1 inhibitors in esophageal cancer-a first step in a new therapeutic directionElaine M Walsh, Ronan J Kelly
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|April 18, 2013
Chemotherapeutic and targeted strategies for locally advanced and metastatic esophageal cancerPatrick M Forde, Ronan J Kelly
Journal of Immunotoxicology|November 18, 2009
Transforming growth factor-beta: a target for cancer therapyRonan J Kelly, John C Morris
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|October 25, 2016
Checkpoint Inhibitors in Lung Cancer Are Not Immune from Cost-Effectiveness AnalysisRonan J Kelly, Thomas J Smith
The Oncologist|July 16, 2013
Genomic alterations in advanced esophageal cancer may lead to subtype-specific therapiesPatrick M Forde, Ronan J Kelly
The Lancet. Oncology|February 19, 2014
Delivering maximum clinical benefit at an affordable price: engaging stakeholders in cancer careRonan J Kelly, Thomas J Smith
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|December 17, 2009
Antiangiogenesis induced tumor cavitation in lung cancerRonan J Kelly, Oleh Hnatiuk, Giuseppe Giaccone
Pageof 11

Showing results (11-20 of 109) with videos related to

Sort By:
Pageof 11
Targeted Oncology|October 31, 2009
Axitinib--a selective inhibitor of the vascular endothelial growth factor (VEGF) receptorRonan J Kelly, Olivier Rixe
Gastroenterology Research and Practice|March 19, 2015
From molecular classification to targeted therapeutics: the changing face of systemic therapy in metastatic gastroesophageal cancerAdrian Murphy, Ronan J Kelly
Hematology/Oncology Clinics of North America|May 15, 2017
The Evolving Role of Checkpoint Inhibitors in the Management of Gastroesophageal CancerAdrian G Murphy, Ronan J Kelly
Journal of Thoracic Disease|May 1, 2018
Single agent anti PD-1 inhibitors in esophageal cancer-a first step in a new therapeutic directionElaine M Walsh, Ronan J Kelly
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|April 18, 2013
Chemotherapeutic and targeted strategies for locally advanced and metastatic esophageal cancerPatrick M Forde, Ronan J Kelly
Journal of Immunotoxicology|November 18, 2009
Transforming growth factor-beta: a target for cancer therapyRonan J Kelly, John C Morris
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|October 25, 2016
Checkpoint Inhibitors in Lung Cancer Are Not Immune from Cost-Effectiveness AnalysisRonan J Kelly, Thomas J Smith
The Oncologist|July 16, 2013
Genomic alterations in advanced esophageal cancer may lead to subtype-specific therapiesPatrick M Forde, Ronan J Kelly
The Lancet. Oncology|February 19, 2014
Delivering maximum clinical benefit at an affordable price: engaging stakeholders in cancer careRonan J Kelly, Thomas J Smith
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|December 17, 2009
Antiangiogenesis induced tumor cavitation in lung cancerRonan J Kelly, Oleh Hnatiuk, Giuseppe Giaccone
Pageof 11